Sector consensus Charles River Laboratories International, Inc. CBOE
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
CBOE
03:59:50 22/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 295.33 USD | +1.32% |
|
+5.47% | +47.92% |
| 08-21 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| 08-20 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 681.13 | +15.02% | 23 | ||||||
| 223.24 | +6.58% | 21 | ||||||
| 275.17 | +5.91% | 18 | ||||||
| 433.02 | +15.63% | 27 | ||||||
| 266,031.64 | +38.34% | 23 | ||||||
| 581.83 | -6.27% | 12 | ||||||
| 268.37 | +23.52% | 19 | ||||||
| 72.53 | -0.43% | 14 | ||||||
| 281 | -4.81% | 14 | ||||||
| 185.56 | +7.74% | 16 | ||||||
| 47.08 | -1.87% | 11 | ||||||
| 63.36 | -12.84% | 14 | ||||||
| 70.73 | -2.2% | 11 | ||||||
| 138.97 | +36.51% | 6 | ||||||
| 638.68 | +69.89% | 19 | ||||||
| 134.85 | +0.07% | 11 | ||||||
| 130.91 | +9.27% | 22 | ||||||
| 88 | +47.3% | 22 | ||||||
| 170.38 | +10.41% | 13 | ||||||
| Average | 14,237.71 | +13.57% | 17 | ||||||
| Weighted average by Cap. | 22,112.96 | +13.17% | 19 |
Select your edition
All financial news and data tailored to specific country editions
